Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Molecular mechanisms of serous ovarian carcinoma development.

FY 2008-09

Summary
Ovarian cancer is the fifth deadliest malignancy among Canadian women. Most cases (75%) are classified as serous tumors; a highly aggressive sub-type that kills 70% of patients within 5 years of diagnosis. A major reason for the high mortality rate is a lack of effective screening tools. Unlike other gynecological malignancies, such as cervical cancer, there is no reliable method for early detection of ovarian cancer. Consequently, most patients are diagnosed with advanced disease. Unfortunately, we know very little about the early stages of this cancer. In order to screen for and effectively treat serous ovarian cancer, it is critical that we understand how it develops. Recent evidence suggests that most serous "ovarian" tumors actually originate from the end of the fallopian tube. It is thought that during ovulation, cells lining the fallopian tube are damaged. Over years, this damage accumulates and transforms fallopian tube cells into cancer, which quickly spreads to the nearby ovary. With this research proposal, we aim to determine exactly how and why fallopian tube cells are transformed and progress to serous tumors. We will accomplish this goal via three complementary approaches: Firstly, we will genetically profile each stage of tumor development, from normal cells to advanced tumors, in order to identify which genes are altered during cancer progression. Secondly, using a novel cell culture model developed by our lab, we will study how fallopian tube cells respond to ovulation-associated stress. And thirdly, we will attempt to re-create fallopian tube cell transformation in order to confirm which genes are involved in cancer initiation. The transformed cells will then be injected into mice to test whether they can develop into advanced serous tumors. This research will provide novel insights into the mechanisms of serous ovarian cancer progression and is crucial for the development of improved prevention and treatment strategies.
Program
CIHR Fellowship
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
179945
Name
Karst Alison M
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Molecular mechanisms of serous ovarian carcinoma development.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cdna Microarray; Cell Culture Model; Dna Damage Response; Mouse Xenograft; Oncogenes; Ovarian Cancer; Snp Microarray; Tumor Initiation; Tumor Progression; Tumor Suppressors
Abstract
Ovarian cancer is the fifth deadliest malignancy among Canadian women. Most cases (75%) are classified as serous tumors; a highly aggressive sub-type that kills 70% of patients within 5 years of diagnosis. A major reason for the high mortality rate is a lack of effective screening tools. Unlike other gynecological malignancies, such as cervical cancer, there is no reliable method for early detection of ovarian cancer. Consequently, most patients are diagnosed with advanced disease. Unfortunately, we know very little about the early stages of this cancer. In order to screen for and effectively treat serous ovarian cancer, it is critical that we understand how it develops. Recent evidence suggests that most serous "ovarian" tumors actually originate from the end of the fallopian tube. It is thought that during ovulation, cells lining the fallopian tube are damaged. Over years, this damage accumulates and transforms fallopian tube cells into cancer, which quickly spreads to the nearby ovary. With this research proposal, we aim to determine exactly how and why fallopian tube cells are transformed and progress to serous tumors. We will accomplish this goal via three complementary approaches: Firstly, we will genetically profile each stage of tumor development, from normal cells to advanced tumors, in order to identify which genes are altered during cancer progression. Secondly, using a novel cell culture model developed by our lab, we will study how fallopian tube cells respond to ovulation-associated stress. And thirdly, we will attempt to re-create fallopian tube cell transformation in order to confirm which genes are involved in cancer initiation. The transformed cells will then be injected into mice to test whether they can develop into advanced serous tumors. This research will provide novel insights into the mechanisms of serous ovarian cancer progression and is crucial for the development of improved prevention and treatment strategies.
Competitiondate
200902
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Karst, Alison M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~